MANHATTAN, Kan. — By understanding the functional differences between proteins expressed by two E. coli strains, researchers at Kansas State University are exploring new opportunities to inhibit their impacts to human health.
The scientists are using findings from their study, "NleB/SseK effectors from Citrobacter rodentium, Escherichia coli, and Salmonella enterica display distinct differences in host substrate specificity," published in the Journal of Biological Chemistry, to start researching new ways to treat two types of E. coli: enterohemorrhagic E. coli and enteropathogenic E. coli.
Enterohemorrhagic E. . .
Register or Login to keep reading
Thank you for your interest in accessing the complete content. To continue reading, please register for free. By registering, you'll gain full access to our valuable resources, updates, and insights.
If you already have an account please Log In.
